Is Australian Pharmaceutical Industries Ltd (ASX: API) a good dividend share after announcing its half year result?
API Pharmaceutical is the pharmacy company behind Priceline, ClearSkincare, Soul Pattinson Chemist and much more. The Melbourne-based company is more than 100 years old and operates more than 500 chemists and hundreds more are included in its member network.
Here’s What API Reported In Its HY19 Report
API revealed to investors that total revenue growth was 6.6% compared to the HY18 result, excluding the Hepatitis C medicine sales and PBS Reforms.
Priceline Pharmacy’s total network sales were $1.1 billion, which was up slightly and total network like for like sales were up 0.3%. The Priceline store network currently sits at 479 stores, but it will persist with the policy of closing stores where landlords have unrealistic rental demands.
The EBIT (click here to learn what EBIT means) grew by 5.8% to $44.4 million, which was ahead of guidance of 5%. The underlying EBITDA grew by 3% to $60.5 million (click here to learn what EBITDA means).
Net profit after tax (NPAT) was 0.2% higher at 0.2%, which includes the impact of financing costs associated with the Sigma Healthcare Ltd (ASX: SIG) share purchase.
However, the underlying net profit was in line with the prior year’s result at $26.8 million. The underlying return on equity (ROE) grew 1.01% to 10.23%.
API Management Comments
API CEO And Managing Director Richard Vincent said: “API’s financial position remains strong and has allowed us to make an investment in Sigma Healthcare, acquire Clear Skincare and provide additional inventory to capitalise on sales opportunities during the half.
“We have a highly complementary portfolio of assets with an attractive growth outlook, which combined during the half to deliver improved earnings and NPAT.”
API Outlook And Dividend
The retail trading for API has been “variable”, but the company expects to deliver positive growth again in the second half of the year.
The API Board declared a fully franked interim dividend of 3.75 cents per share, which was an increase of 7.1%, which represents a payout ratio of 77% of the half.
It currently has a fully franked dividend yield of 5.3%, so it has an attractive dividend yield and might be a decent idea for income. However, it is delivering little growth at the moment, so one of the shares revealed in the free report below could be better picks.
Here are 3 stocks I own in April 2020...
Amidst the COVID-19 confusion, there are some companies still growing FAST (think: online meetings through Zoom, streaming companies like Netflix and eHealth services provided by Teledoc).
While the world grapples with COVID-19, some companies are still growing rapidly. The entire cloud computing market is valued around $US210 billion but if you ask me, it seems clear as day that this market is only going to get bigger in 2020 and beyond.
That's why our top investment analyst has just identified 3 growth stocks in a net cash position, with strong competitive forces... and obvious tailwinds at their back. He owns all three of them right now!
Claim a FREE investing report on our analyst's "3 best share ideas for the cloud revolution" when you create a free Rask Australia account.
Our report is 100% free and unlocks hundreds of hours of bonus content.
Disclaimer and warning: The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms of Service and Financial Services Guide before using this website.
At the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.